Niklas Mattsson

44.0k total citations · 26 hit papers
314 papers, 19.5k citations indexed

About

Niklas Mattsson is a scholar working on Physiology, Psychiatry and Mental health and Neurology. According to data from OpenAlex, Niklas Mattsson has authored 314 papers receiving a total of 19.5k indexed citations (citations by other indexed papers that have themselves been cited), including 212 papers in Physiology, 197 papers in Psychiatry and Mental health and 56 papers in Neurology. Recurrent topics in Niklas Mattsson's work include Alzheimer's disease research and treatments (204 papers), Dementia and Cognitive Impairment Research (190 papers) and Neurological Disease Mechanisms and Treatments (37 papers). Niklas Mattsson is often cited by papers focused on Alzheimer's disease research and treatments (204 papers), Dementia and Cognitive Impairment Research (190 papers) and Neurological Disease Mechanisms and Treatments (37 papers). Niklas Mattsson collaborates with scholars based in Sweden, United States and United Kingdom. Niklas Mattsson's co-authors include Henrik Zetterberg, Kaj Blennow, Oskar Hansson, Sebastian Palmqvist, Erik Stomrud, Ulf Andréasson, Shorena Janelidze, Michael W. Weiner, Philip S. Insel and Ruben Smith and has published in prestigious journals such as JAMA, Nature Medicine and Nature Communications.

In The Last Decade

Niklas Mattsson

294 papers receiving 19.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

2009 822 citations Niklas Mattsson profile →
Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

2020 765 citations Shorena Janelidze, Niklas Mattsson et al. Nature Medicine profile →
Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease

2017 698 citations Niklas Mattsson, Henrik Zetterberg et al. JAMA Neurology profile →
Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity

2017 576 citations Sebastian Palmqvist, Michael Schöll et al. Nature Communications profile →
Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease

2019 470 citations Niklas Mattsson, Nicholas Cullen et al. JAMA Neurology profile →
Plasma tau in Alzheimer disease

2016 378 citations Niklas Mattsson, Henrik Zetterberg et al. profile →
Amyloid biomarkers in Alzheimer's disease

2015 353 citations Kaj Blennow, Niklas Mattsson et al. profile →
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression

2015 347 citations Henrik Zetterberg, Niklas Mattsson et al. JAMA Neurology profile →
Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures

2021 324 citations Sebastian Palmqvist, Pontus Tideman et al. Nature Medicine profile →
CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease

2016 321 citations Shorena Janelidze, Henrik Zetterberg et al. profile →
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease

2021 310 citations Joana B. Pereira, Shorena Janelidze et al. Brain profile →
Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status

2019 299 citations Sebastian Palmqvist, Shorena Janelidze et al. JAMA Neurology profile →
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease

2020 292 citations Shorena Janelidze, Erik Stomrud et al. Nature Communications profile →
Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease

2019 230 citations Sebastian Palmqvist, Philip S. Insel et al. profile →
Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease

2020 222 citations Shorena Janelidze, David Berron et al. JAMA Neurology profile →
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

2020 217 citations Niklas Mattsson, Shorena Janelidze et al. profile →
Blood‐based biomarkers for Alzheimer's disease

2021 196 citations Antoine Leuzy, Niklas Mattsson et al. profile →
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment

2021 190 citations Claudia Cicognola, Shorena Janelidze et al. Alzheimer s Research & Therapy profile →
Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations

2021 171 citations Nicholas Cullen, Antoine Leuzy et al. Nature Communications profile →
Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers

2023 150 citations Niklas Mattsson, Gemma Salvadó et al. JAMA Neurology profile →
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance

2022 127 citations Alexa Pichet Binette, Shorena Janelidze et al. Alzheimer s & Dementia profile →
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads

2023 92 citations Gemma Salvadó, Rik Ossenkoppele et al. profile →
Clinical effects of Lewy body pathology in cognitively impaired individuals

2023 91 citations Sebastian Palmqvist, Shorena Janelidze et al. Nature Medicine profile →
Cognitive effects of Lewy body pathology in clinically unimpaired individuals

2023 80 citations Sebastian Palmqvist, Niklas Mattsson et al. Nature Medicine profile →
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment

2024 42 citations Shorena Janelidze, Gemma Salvadó et al. JAMA Neurology profile →
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease

2025 27 citations Gemma Salvadó, Shorena Janelidze et al. Nature Medicine profile →

Peers

Countries citing papers authored by Niklas Mattsson

Since Specialization

Citations

This map shows the geographic impact of Niklas Mattsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Niklas Mattsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Niklas Mattsson more than expected).

Fields of papers citing papers by Niklas Mattsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Niklas Mattsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Niklas Mattsson. The network helps show where Niklas Mattsson may publish in the future.

Co-authorship network of co-authors of Niklas Mattsson

This figure shows the co-authorship network connecting the top 25 collaborators of Niklas Mattsson. A scholar is included among the top collaborators of Niklas Mattsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Niklas Mattsson. Niklas Mattsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Diagnostic and Prognostic Value of Blood and Cerebrospinal Fluid Biomarkers in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta‐Analysis 2025 ·European Journal of Neurology ·(unknown), Daisuke Ito, Christer Nilsson, Shorena Janelidze, Alexander Santillo, Masahisa Katsuno, Niklas Mattsson	0
2	APOE4 impact on soluble and insoluble tau pathology is mostly influenced by amyloid-β 2025 ·Brain ·Claudia Cicognola, Gemma Salvadó, Ruben Smith, Sebastian Palmqvist, Erik Stomrud, Tobey J. Betthauser, (unknown), Shorena Janelidze, Niklas Mattsson, Oskar Hansson, Alexa Pichet Binette	3
3	Primary care detection of Alzheimer’s disease using a self-administered digital cognitive test and blood biomarkers 2025 ·Nature Medicine ·Pontus Tideman, (unknown), Olof Strandberg, Susanna Calling, Ruben Smith, Patrik Midlöv, Philip B. Verghese, Joel B. Braunstein, Niklas Mattsson, Erik Stomrud, Sebastian Palmqvist, Oskar Hansson	0
4	Complementary utility of plasma biomarkers and Aβ‐PET for diagnosis, risk‐stratification, and treatment monitoring in Alzheimer's disease 2025 ·Alzheimer s & Dementia ·Lyduine E. Collij, Niklas Mattsson, Shorena Janelidze, Rik Ossenkoppele, Oskar Hansson	1
5	Longitudinal tau aggregation, atrophy, and cognitive decline in Alzheimer's disease 2025 ·Alzheimer s & Dementia ·(unknown), Niklas Mattsson, Alexa Pichet Binette, Erik Stomrud, Olof Strandberg, Sebastian Palmqvist, Rik Ossenkoppele, Oskar Hansson	4
6	A blood-based biomarker workflow for optimal tau-PET referral in memory clinic settings 2024 ·Nature Communications ·Wagner S. Brum, Nicholas Cullen, Joseph Therriault, Shorena Janelidze, Nesrine Rahmouni, Jenna Stevenson, Stijn Servaes, Andréa Lessa Benedet, Eduardo R. Zimmer, Erik Stomrud, Sebastian Palmqvist, Henrik Zetterberg, Giovanni B. Frisoni, Nicholas J. Ashton, Kaj Blennow, Niklas Mattsson, Pedro Rosa‐Neto, Oskar Hansson	15
7	Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases 2024 ·Nature Communications ·(unknown), Jacob W. Vogel, (unknown), Kalle Åström, Shorena Janelidze, Kaj Blennow, Sebastian Palmqvist, Erik Stomrud, Niklas Mattsson, Oskar Hansson	14
8	Evaluation of the prospective use of blood biomarkers for Alzheimer’s disease in primary and secondary care 2024 ·Alzheimer s & Dementia ·Sebastian Palmqvist, Gemma Salvadó, Niklas Mattsson, Tim West, Ruben Smith, Rik Ossenkoppele, Suzanne E. Schindler, Kaj Blennow, Mark Monane, Philip B. Verghese, Joel B. Braunstein, Shorena Janelidze, Erik Stomrud, Pontus Tideman, Oskar Hansson	0
9	Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer’s Disease 2024 ·Molecular Neurodegeneration ·Juan Lantero‐Rodriguez, Gemma Salvadó, Anniina Snellman, Laia Montoliu‐Gaya, Wagner S. Brum, Andréa L. Benedet, Niklas Mattsson, Pontus Tideman, Shorena Janelidze, Sebastian Palmqvist, Erik Stomrud, Nicholas J. Ashton, Henrik Zetterberg, Kaj Blennow, Oskar Hansson	13
10	Biological mechanisms of resilience to tau pathology in Alzheimer’s disease 2024 ·Alzheimer s Research & Therapy ·Anna L. Svenningsson, (unknown), Erik Stomrud, (unknown), Frederik Barkhof, Niklas Mattsson, Sebastian Palmqvist, Oskar Hansson, Rik Ossenkoppele	0
11	Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment 2024 ·JAMA Neurology ·Colin Groot, Ruben Smith, Lyduine E. Collij, Sophie E Mastenbroek, Erik Stomrud, Alexa Pichet Binette, Antoine Leuzy, Sebastian Palmqvist, Niklas Mattsson, Olof Strandberg, Hanna Cho, Chul Hyoung Lyoo, Giovanni B. Frisoni, Débora Elisa Peretti, Valentina Garibotto, Renaud La Joie, David N. Soleimani‐Meigooni, Gil D. Rabinovici, Rik Ossenkoppele, Oskar Hansson	21
12	Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease 2023 ·Brain Communications ·Nicholas Cullen, Shorena Janelidze, Erik Stomrud, Randall J. Bateman, Sebastian Palmqvist, Oskar Hansson, Niklas Mattsson	5
13	Age-related and amyloid-beta-independent tau deposition and its downstream effects 2023 ·Brain ·Anika Wuestefeld, Alexa Pichet Binette, David Berron, Nicola Spotorno, Danielle van Westen, Erik Stomrud, Niklas Mattsson, Olof Strandberg, Ruben Smith, Sebastian Palmqvist, (unknown), (unknown), Michael Honer, Konstantinos Arfanakis, Lisa L. Barnes, David A. Bennett, Julie A. Schneider, Laura E.M. Wisse, Oskar Hansson	25
14	Carbon dioxide flooding to reduce postoperative neurological injury following surgery for acute type A aortic dissection: a prospective, randomised, blinded, controlled clinical trial, CARTA study protocol - objectives and design 2023 ·BMJ Open ·(unknown), (unknown), Marion Moseby‐Knappe, Birgitta Ramgren, Henrik Bjursten, Per Ederoth, Mårten Larsson, Niklas Mattsson, Johan Sjögren, Per Wierup, Shahab Nozohoor, Igor Zindovic	0
15	Serum neurofilament light levels are correlated to long-term neurocognitive outcome measures after cardiac arrest 2022 ·Brain Injury ·Erik Nordström, Gisela Lilja, Susann Ullén, Kaj Blennow, Hans Friberg, Christian Hassager, Jesper Kjærgaard, Niklas Mattsson, Marion Moseby‐Knappe, Niklas Nielsen, Susanna Vestberg, Henrik Zetterberg, Tobias Cronberg	10
16	Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer’s disease 2020 ·Brain ·Joana B. Pereira, Shorena Janelidze, Rik Ossenkoppele, Hlin Kvartsberg, Ann Brinkmalm, Niklas Mattsson, Erik Stomrud, Ruben Smith, Henrik Zetterberg, Kaj Blennow, Oskar Hansson	142
17	CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers 2020 ·Scientific Reports ·Shahzad Ahmad, Marta del Campo, Oskar Hansson, Ayşe Demirkan, Agustı́n Ruiz, María Eugenia Sáez, Νικόλαος Γιαγτζόγλου, Alfredo Cabrera‐Socorro, Margot H.M. Bakker, Alfredo Ramı́rez, Thomas Hankemeier, Erik Stomrud, Niklas Mattsson, Philip Scheltens, Wiesje M. van der Flier, M. Arfan Ikram, Anders Mälarstig, Charlotte E. Teunissen, Najaf Amin, Cornelia M. van Duijn	18
18	Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment 2018 ·International Journal of Geriatric Psychiatry ·Mitzi M. Gonzales, Philip S. Insel, Craig Nelson, Duygu Tosun, Michael Schöll, Niklas Mattsson, Simona Sacuiu, David Bickford, Michael W. Weiner, R. Scott Mackin, (unknown)	20
19	Chronic Depressive Symptomatology in Mild Cognitive Impairment Is Associated with Frontal Atrophy Rate which Hastens Conversion to Alzheimer Dementia 2015 ·American Journal of Geriatric Psychiatry ·Simona Sacuiu, Philip S. Insel, Susanne G. Mueller, Duygu Tosun, Niklas Mattsson, Clifford R. Jack, Charles DeCarli, Ronald Petersen, Paul Aisen, Michael W. Weiner, R. Scott Mackin	59
20	Automated cerebrospinal fluid cell count — New reference ranges and evaluation of its clinical use in central nervous system infections 2013 ·Clinical Biochemistry ·Daniel Bremell, Niklas Mattsson, Fredrik Wallin, (unknown), (unknown), Kaj Blennow, Henrik Zetterberg, Lars Hagberg	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact